Zurück
Weiter
|
| Tagestief | 0,01 | Tageshoch | 0,02 |
| 52 W. Tief | 0,00 | 52 W. Hoch | 0,77 |
| Volumen (Stück) | 125.000 | Börse | NAS |
Kann mir vielleicht jemand erklären wie der Wert eines Papier an einem Handelsplatz von anderen Börsenplätzen partizipiert. Ich meine ist das progressives Hinterhergeschleife oder so?
Ich Frage deshalb, da ich mit meinem broker genta nur an der xetra oder frankfurter börse kaufen bzw. verkaufen kann (da handelt keine sau) und hab da irgendwie noch nicht das Muster entdecken können, das ich doch so gern gefunden hätte.... ;(
Gruss
grad gingen ein paar mega orders über den Tisch...
4x 2,5 mio
2 x 3,0 mio
BERKELEY HEIGHTS, NJ - May 19, 2009 - Genta Incorporated (OTCBB: GNTA.OB) today announced that the independent Data Monitoring Board (DMB) for AGENDA, a randomized Phase 3 trial of Genasense® in patients with advanced melanoma, has informed the Company that the study has passed its final futility analysis for progression-free survival (PFS). Accordingly, the Board has recommended that the study should continue to completion.
Coincident with this recommendation, Genta has submitted an "intent-to-file" notice via the centralized procedure to the European Medicines Agency (EMEA), along with a request for assignment of rapporteurs. Such notice is required prior to submission of a Marketing Authorization Application (MAA).
"Futility analyses after completing accrual have been occasions for failure of two other Phase 3 melanoma drugs earlier this year," said Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer. "Having announced enrollment completion last month, we are greatly pleased with this report from the DMB for AGENDA. The next milestone is release of final data on progression-free survival (PFS), which is expected in the 4th quarter of this year. If positive, we expect our regulatory applications for Genasense will be based on statistically significant and clinically meaningful improvements in PFS."
AGENDA is a randomized double-blind trial in 315 patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from a previous randomized trial of Genasense combined with dacarbazine in patients who have not previously received chemotherapy. AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH, a tumor-derived enzyme that is readily detected in blood. In large trials like AGENDA, one or more analyses for "futility" are commonly conducted by an independent committee to determine whether there is no longer a reasonable chance that a trial will achieve its major endpoints. AGENDA has co-primary endpoints of PFS and overall survival (OS), and subsequent futility analyses for OS are planned if the PFS endpoint is achieved. AGENDA is intended to support global registration of Genasense for patients with advanced melanoma.
http://www.genta.com/investor%20relations/...D=433&SHID=&COID=
vergißt die Vanda nicht... wenn der gesunde Menschenverstand nicht wäre!? Oder doch Gier? ....Scheiß was drauf, ICH kaufe nach! ;-)
|
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 302 | Gensense ist Tod es lebe Tesetaxel! | raurunter | raurunter | 25.04.21 13:15 | |
| 10 | 2.653 | Die 1000% Chance noch dieses Jahr.... | Happydepot | steven-bln | 25.04.21 13:13 | |
| 13 | 2.456 | Analyse. GENTA Kursexplosionsgefahr!! | brunneta | steven-bln | 25.04.21 02:54 | |
| 4 | 1.447 | was mit der Aktie passiert, etc.. | Lucky2020 | Lucky2020 | 25.04.21 02:10 | |
| 622 | Hoffnung stirbt zum Schluss...! | raurunter | raurunter | 25.04.21 00:48 |
